Acellular Hip Implant for Cartilage Repair
Osteoarthritis / Cartilage Defects of the Hip
Key Facts
About CytexOrtho
CytexOrtho is pioneering a regenerative medicine approach to address the significant unmet need in early-stage osteoarthritis, particularly for younger, active patients who wish to avoid total joint replacement. The company's core technology is an acellular, tissue-engineered implant designed to resurface and repair damaged cartilage in joints like the hip. Having secured FDA approval to initiate a pilot clinical study in October 2024, CytexOrtho is transitioning from pre-clinical development into the clinical validation stage. The company is led by a scientifically strong team with deep expertise in tissue engineering and orthopedic surgery, positioning it to tap into the multi-billion dollar joint preservation market.
View full company profile